Mipomersen (INN; trade name Kynamro) is a drug used to treat homozygous familial hypercholesterolemia and is administered by subcutaneous injection. There is a serious risk of …

Mar 25, 2025 · KYNAMRO ® is an oligonucleotide inhibitor of apolipoprotein B-100 synthesis indicated as an adjunct to lipid-lowering medications and diet to reduce low density lipoprotein …

KYNAMRO® is indicated as an adjunct to lipid-lowering medications and diet to reduce low density lipoprotein-cholesterol (LDL-C), apolipoprotein B (apo B), total cholesterol (TC), and …

KYNAMRO™ is an oligonucleotide inhibitor of apolipoprotein B-100 synthesis indicated as an adjunct to lipid-lowering medications and diet to reduce low density lipoprotein-cholesterol …

Jun 28, 2024 · Kynamro is a cholesterol-lowering medication. It reduces blood levels of "bad" cholesterol, such as low-density lipoprotein (LDL), apolipoprotein-B (apo-B), or non-high …

Jan 29, 2013 · The U.S. Food and Drug Administration today approved Kynamro (mipomersen sodium) injection as an addition to lipid-lowering medications and diet to treat patients with a …

Jan 17, 2017 · KYNAMRO- mipomersen sodium injection, solution If this SPL contains inactivated NDCs listed by the FDA initiated compliance action, they will be specified as such.

Nov 29, 2021 · Kynamro (mipomersen sodium) Injection is an oligonucleotide inhibitor of apo B-100 synthesis used as an adjunct to lipid -lowering medications and diet to reduce low density …

Mipomersen is a second generation antisense oligonucleotide that targets apolipoprotein B. It has been studied thoroughly in clinical trials (more than 800 subjects), including four randomized …

May 21, 2024 · Detailed dosage guidelines and administration information for Kynamro (mipomersen sodium). Includes dose adjustments, warnings and precautions.